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Abstract 
Hypercortisolism induces a state of insulin resistance that can occur concurrently with fasting hyperglycaemia, 
dyslipidaemia and diabetes mellitus. Metformin reduces hepatic glucose production and insulin resistance of the 
skeletal muscle and adipose tissue. The aim of this study was to evaluate the effects of metformin on the control of 
metabolic disorders of dogs with hyperadrenocorticism (HAC). Twenty-three dogs with HAC were randomly divided 
into two groups, consisting of a control group and a metformin group (10 mg metformin/kg/12 h). Both groups 
received the same treatment for HAC. At baseline and 3 months, blood glucose, total cholesterol, triglycerides and 
insulin concentrations, in addition to urinary cortisol:creatinine ratio, Homeostatic Model Assessment (HOMA) for 
insulin sensitivity and β-cell function were measured. Dogs treated with metformin showed significantly reduced 
glycaemia, cholesterolaemia and triglyceridaemia. They also presented reduced hyperinsulinism and insulin 
resistance, as well as improved pancreatic β-cell function. The implementation of metformin as an adjuvant therapy 
is effective for the normalisation of metabolic disorders of dogs with HAC. 




Cortisol antagonises various functions of insulin, and 
high levels may predispose an individual to insulin 
resistance, a condition in which the peripheral tissues 
have a reduced response to insulin (Andrews and 
Walker, 1999; Miceli et al., 2014; Mazziotti et al., 
2017). Indeed, the antagonism of insulin by cortisol is 
so potent that the glucocorticoid effects are referred to 
as “diabetogenic” (Van Raalte et al., 2009; Van Raalte 
and Diamant, 2014). Chronic hypercortisolism 
stimulates hepatic gluconeogenesis, interfering with the 
insulin signalling cascade and glucose uptake in the 
skeletal muscle and adipose tissue, in addition to 
affecting the insulin synthesis and secretion of 
pancreatic β-cells, as well as inducing their apoptosis 
(Schӓcke et al., 2002; Vegiopoulos and Herzig, 2007). 
These metabolic disorders are clinically characterised 
by fasting hyperglycaemia, hypercholesterolaemia, 
hypertriglyceridaemia, abdominal obesity, hepatic 
steatosis and diabetes mellitus (Peterson et al., 1984; 
Pivonello et al., 2010; Di Dalmazi et al., 2012). 
Between 5% and 22% of dogs with HAC develop 
diabetes mellitus (Peterson et al., 1981; Nichols, 1994; 
Ishino et al., 2010; Gomes Pöppl et al., 2016; Miceli et 
al., 2017).  
Homeostatic Model Assessment indices (HOMA) are 
used to evaluate both peripheral insulin sensitivity 
(HOMAinsulin sensitivity) and the function of pancreatic β-
cells to produce insulin (HOMAβ-cell function) (Matthews 
et al., 1985; Verkest et al., 2010; Miceli et al., 2014). 
Metformin is a biguanide that is commonly used as an 
oral antidiabetic medication for the treatment of type 2 
diabetes mellitus in humans (Herman et al., 2005; 
Aroda et al., 2015; American Diabetes Association, 
2016). Metformin reduces hepatic glucose production 
and insulin resistance in peripheral tissues (especially 
the skeletal muscle and adipose tissue), therefore, 
metformin is considered an “insulin-sensitising” drug 
(Natali and Ferrannini, 2006). 
The effects of metformin are not immediate as it acts 
by modifying the gene expression of key enzymes 
involved in metabolic regulation (Foretz et al., 2014). 
In the liver, metformin inhibits gluconeogenesis and 
glycogenolysis, and stimulates glycogenesis (Zhou et 
al., 2001). In the adipose tissue and skeletal muscle, 
metformin increases the number and affinity of insulin 
receptors, the tyrosine kinase activity of the insulin 
receptor, and the translocation and intrinsic activity of 
GLUT-4 (glucose transporter type 4) (Natali and 
Ferrannini, 2006; Geerling et al., 2014). 
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In veterinary medicine, metformin can be used to treat 
cats with diabetes mellitus, but only in cases where the 
patient has a functional reserve of pancreatic β-cells 
(Nelson et al., 2004). In dogs, experimental studies 
have been performed to evaluate the hepatic effects of 
metformin (Chu et al., 2000), but it is not routinely used 
as a treatment. In dogs with HAC, the effects of 
metformin treatment remain unknown. The purpose of 
this study was to evaluate the therapeutic actions of 
metformin for controlling the tendency toward 
hyperglycaemia, hypercholesterolaemia, 
hypertriglyceridaemia, hyperinsulinism and insulin 
resistance in dogs with HAC. 
Materials and Methods 
Study population 
Twenty-three dogs (n = 23) with pituitary-dependant 
hyperadrenocorticism (PDH) were studied. The 
diagnosis of PDH was based on history (polydypsia, 
polyuria and polyphagia, panting, persistent anestrous 
and any other typical sign of the disease), physical 
examination (alopecia, prominent abdomen, thin 
inelastic skin, muscular atrophy), routine laboratory 
findings (stress leukogram, mild hyperglycaemia, 
dyslipidaemia, increased alkaline phosphatase or 
alanine transferase, low urine specific gravity) and an 
increased urine cortisol:creatinine ratio (UCCR) in two 
consecutive morning urine samples collected by the 
owner at home. After collection of the second urine 
sample, three doses of dexamethasone (0.1 mg/kg) 
were administered PO at 8-hour intervals, and a third 
urine sample was collected the following morning, 
according to Kooistra and Galac (2012). The diagnosis 
was further supported by visualisation of the adrenal 
glands by ultrasonography and the pituitary gland by 
nuclear magnetic resonance imaging. Abdominal 
ultrasonography revealed bilateral adrenal hyperplasia 
and no evidence of an adrenocortical tumor in any of 
these 23 dogs. Nuclear magnetic resonance imaging 
revealed a pituitary mass in all dogs. Dogs with an 
infectious disease (systemic or local), pancreatitis, 
diabetes mellitus, hypothyroidism, tumours (except 
pituitary adenoma) or any other systemic disorder 
capable of inducing insulin resistance were excluded 
(Hess, 2010). Also, dog with abnormalities on 
Complete Blood Count (CBC), urinalysis or 
biochemical profile other than those expected with 
PDH (stress leukogram, low urine specific gravity, mild 
hyperglycaemia, dyslipidaemia, increased alkaline 
phosphatase or alanine transferase), were excluded. 
Likewise, no dog with increased Blood Urea Nitrogen 
(BUN) was included. In all cases, the common therapy 
used in Argentina was administered, consisting of 
combined treatment with cabergoline (0.07 
mg/kg/week, divided into doses administered every 48 
hours) and ketoconazole (20 mg/kg administered every 
24 hours) (Castillo et al., 2008; Lien and Huang, 2008). 
The 23 dogs with HAC were randomly divided into two 
groups: (1) control group (n = 10; six females and four 
males; all were non-castrated; median age of 8.5 years, 
range 6 to 14 years); or (2) metformin group (n = 13; 
eight females and five males; two castrated females; 
median age of 9 years, range 7 to 13 years), for which 
metformin was administered at a dose of 10 mg/kg 
every 12 hours with food. In cases of intolerance, 
metformin was administered gradually (first week: 2.5 
mg/kg/12 h, second week: 5 mg/kg/12 h, third week: 
7.5 mg/kg/12 h, and finally the total dose of 10 
mg/kg/12 h). All the non-castrated females had low 
progesterone levels (< 2 nmol/L), both at the beginning 
and at the end of the treatment (data not shown), so that 
the progesterone insulin antagonism was ruled out. 
None of the dogs showed any clinical signs or 
biochemical abnormalities (both serum and urine) 
characteristic of liver or kidney disease that might have 
exacerbated the adverse effects of metformin. 
Hormone and biochemical measurements 
Glucose, triglycerides, total cholesterol, insulin and 
UCCR were measured. Blood samples were collected 
at the same time for all dogs after a 12-hour fast from 
solid food, both at the time of diagnosis (basal time 
point) and 3 months after starting treatment. Blood 
glucose was assessed using an automated laboratory 
method (Metrolab Autoanalyzer; Merck, Germany) 
according to the manufacturer’s instructions. Blood 
samples for glucose analysis were collected in glass 
tubes containing sodium fluoride and EDTA as the 
anticoagulant (Anticoagulant G; Wiener Laboratory, 
Argentina). Blood samples for triglycerides and total 
cholesterol analysis were collected in another tube and 
measured by an automated laboratory method 
(Metrolab Autoanalyzer; Merck), according to the 
manufacturer’s instructions.  
Insulin concentrations were measured by a specific 
Enzyme-Linked ImmunoSorbent Assay (ELISA) for 
dogs and pigs (Porcine/Canine Insulin ELISA; Alpco, 
USA), with intra- and interassay variation coefficients 
(canine performance) of 4.2% and 4.3%, respectively, 
and sensitivity of 0.007 ng/mL. 
Urine cortisol was measured by radioimmunoassay 
(RIA) using a commercial kit (DPC Corporation, San 
Diego, CA, USA). The inter- and intra-assay 
coefficients of variation for cortisol were 8% and 5%, 
respectively. Creatinine was measured by an automated 
method (Metrolab Autoanalyzer; Merck) according to 
the manufacturer’s instructions. 
HOMA for insulin sensitivity and β-cell function 
Both fasting insulin sensitivity and the role of 
pancreatic β-cells were assessed by HOMA. The 
HOMAinsulin sensitivity and HOMAβ-cell function were 
calculated with nonlinear formulas (Levy et al., 1998) 
using HOMA Calculator version 2.2.2 (Diabetes Trial 
Unit, University of Oxford, UK; 
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according to the methods previously described (Verkest 
et al., 2010; Miceli et al., 2014). In those cases in which 
insulin concentrations exceeded the maximum value 
allowed by the HOMA calculator, the mathematical 
formula (Matthews et al., 1985) was used to calculate 
the aforementioned indices: 
HOMAinsulin sensitivity: ([Glucose] x [Insulin]) / 22.5 
HOMAβ -cell function: (20 x [Insulin] / [Glucose] − 3.5) 
Statistical analysis 
The intra- and intergroup comparisons were performed 
using nonparametric tests, the Wilcoxon rank test and 
Mann-Whitney U test, respectively. Data are expressed 
as the median and interquartile range. The level of 
significance was set at P < 0.05. The statistical analysis 
were performed using GraphPad Prism 6.0 software 
(GraphPad software Inc.). 
Ethical approval 
The Ethics Committee of the Faculty of Veterinary 
Science (CICUAL) and the Office of Science at the 
University of Buenos Aires approved the present study, 
according to the laws on experimentation in animals in 
Argentina, as well as the recommendations of the 
World Health Organization. Signed consent was 
obtained from the owners of all dogs prior to their 
participation in this project. 
Results 
Clinical appearance 
In 5/13 dogs treated with metformin (38.46%), we 
observed some degree of drug intolerance. The most 
common adverse effects were gastrointestinal 
symptoms, including diarrhoea, inappetence and 
vomiting. Diarrhoea was the most frequently observed 
adverse effect. In these five cases, metformin was 
administered at gradually increasing doses, progressing 
from 2.5 mg/kg/12 h during the first week, then 5 
mg/kg/12 h, then 7.5 mg/kg/12 h, and finally the total 
dose of 10 mg/kg/12 h. No dogs were excluded from 
the study, and none showed signs of lactic acidosis. No 
dogs developed diabetes mellitus, at least during the 
first 3 months of treatment. 
Blood glucose, triglycerides and total cholesterol 
concentrations 
When comparing the basal time blood glucose [control 
group: median 5.93 mmol/L (interquartile range 4.1–
6.2), metformin group: 6.38 mmol/L (5.3–6.9)], 
triglycerides [control group: 1.6 mmol/L (1.3–2.6), 
metformin group: 2.3 mmol/L (1.9–3.7)] and total 
cholesterol concentrations [control group: 7.8 mmol/L 
(6.1–11.5), meformin group: 9.9 mmol/L (7.3–12.3)] 
between the groups, no significant differences were 
observed (Fig. 1 and 2). In the metformin group, blood 
glucose (P < 0.01), triglycerides (P < 0.05) and total 
cholesterol (P < 0.01) concentrations were significantly 
reduced after 3 months of treatment (Table 1).  
 
Table 1. Blood glucose, triglycerides, total cholesterol and 
insulin concentrations and urine cortisol:creatinine ratio 
(UCCR) in dogs with hyperadrenocorticism (with or without 
metformin) at basal time and after 3 months of treatment. 
 
Parameter 
Control group Metformin group 




















































Values are expressed as median and interquartile range. Reference 
values: (Glucose: 3.36–6.72 mmol/L); (Triglycerides: 0.5–1.5 
mmol/L); (Total cholesterol: 2.6–6.5 mmol/L); (Insulin: 35.9–179.5 
pmol/L); (UCCR: <10 × 10-6). Significant intragroup difference 
between basal and 3 months indicated by: (***: P < 0.001); (**: P < 
0.01) and (*: P < 0.05). Significant intergroup difference at 3 months 
indicated by: (a: P < 0.01); (b: P < 0.05) and (c: P < 0.05). 
 
 
Fig. 1. Comparison of the blood glucose concentration of 
dogs with hyperadrenocorticism, with or without metformin 
treatment, at basal time and after 3 months of treatment. ** P 
< 0.01 vs. basal time; a P < 0.01 vs. 3 months of control group. 
The dotted line indicates the glucose upper limit of the 
reference range (6.72 mmol/L) and into shadow area the 
values considering as fasting glucose intolerance. 
 
In the control group, no significant differences were 
observed between the basal time measurements and 
those taken at 3 months for the three variables analysed. 
Comparing the concentrations between each group at 3 
months, only blood glucose [control group: 5.71 
mmol/L (5.2–6.8), metformin group: 4.76 mmol/L 
(4.1–5.5)] and triglycerides concentrations [control 
group: 2.0 mmol/L (1.6–2.6), metformin group: 1.1 
mmol/L (0.7–1.8)] differed significantly (P < 0.01 and 
P < 0.05, respectively), with lower concentrations than 
the control group. 
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Fig. 2. Comparison of the blood triglycerides (A) and Total 
cholesterol (B) concentrations of dogs with 
hyperadrenocorticism, with or without metformin treatment, 
at basal time and after 3 months of tratment. A) * P < 0.05; a 
P < 0.05 vs. 3 months of control group; B) ** P < 0.01. The 
dotted line indicates the upper limit of the reference range (A: 
1.5 mmol/L; B: 6.5 mmol/L). 
 
Analysing the individual variation, the blood glucose 
concentration decreased in 13/13 dogs in the metformin 
group, and the triglycerides and total cholesterol 
concentrations decreased in 11/13 dogs (84.61%), with 
the concentrations increasing in the remaining two 
dogs. In the control group, blood glucose levels were 
decreased in 4/10 dogs (40%), increased in 4/10 dogs 
(40%) and remained constant in 2/10 dogs (20%). 
Triglycerides concentrations decreased in 3/10 dogs 
(30%), increased in 2/10 dogs (20%) and remained 
constant in 5/10 dogs (50%). Total cholesterol 
concentrations decreased in 5/10 dogs (50%) and 
remained constant in 5/10 dogs (50%) of the control 
group. 
Insulin concentration and urine cortisol:creatinine 
ratio 
When the basal time insulin concentrations (Fig.3) 
were compared amongst the groups [control group: 185 
pmol/L (97–406), metformin group: 180 pmol/L (90–
430)], no significant differences were observed. 
However, at 3 months, the insulin levels were 
significantly lower in the metformin group [110 pmol/L 
(75–299)] than in the control group [165 pmol/L (80–
340)] (P < 0.05). 
 
Fig. 3. Comparison of the blood insulin concentration of dogs 
with hyperadrenocorticism, with or without metformin 
treatment, at basal time and after 3 months of treatment. * P 
< 0.05; *** P < 0.001; c P < 0.05 vs. 3 months of control 
group. The dotted line indicates the upper limit of the 
reference range (173 pmol/L). 
 
For the intragroup variation, insulin levels were 
significantly decreased after 3 months of treatment both 
in the control group (P < 0.05) and in the metformin 
group (P < 0.01), with the most pronounced decrease 
observed in the metformin group. 
When comparing the basal time UCCR between the 
groups, no significant differences were observed. The 
UCCR decreased significantly after 3 months of 
treatment in both groups (P < 0.001) (Table 1). 
Homeostatic model assessment (HOMA) for insulin 
sensitivity and β-cell function 
At basal time, the HOMAinsulin sensitivity (Fig. 4) did not 
show any significant differences between the groups.  
At 3 months, the HOMAinsulin sensitivity of the metformin 
group was higher than the control group (P < 0.05). For 
the intragroup variation, the HOMAinsulin sensitivity was 
significantly increased at 3 months in both the control 
group (P < 0.01) and the metformin group (P < 0.001), 
with the most pronounced increase observed in the 
metformin group. 
At basal time, the HOMAβ-cell function (Fig. 4) showed no 
significant differences between the groups. At 3 
months, the HOMAβ-cell function of the metformin group 
was lower than the control group (P < 0.05). In regard 
to intragroup variation, the HOMAβ-cell function decreased 
significantly at 3 months in both the control group (P < 
0.01) and the metformin group (P < 0.001), with the 
most pronounced decrease observed in the metformin 
group. 
Discussion 
In both dogs and humans with HAC, the comorbidities 
associated with hypercortisolism (hypertension, 
nephropathy, pulmonary thromboembolism, 
pancreatitis and diabetes mellitus) are the cause of 
patient death (Nichols, 1997; Ferraú and Korbonits, 
2015; Miceli et al., 2017).  
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Fig. 4. Homeostatic model assessment (HOMA) for insulin 
sensitivity (A) and β-cell function (B) in dogs with 
hyperadrenocorticism, with or without metformin treatment, 
at basal time and after 3 months of treatment.  (A): (**: P < 
0.05) and (***: P < 0.001); 3 months vs basal intragroup; (a: 
P<0.05) vs 3 months of control group. (B): (** P < 0.01) and 
(*** P < 0.001); 3 months vs basal intragroup; (a: P<0.05) vs 
3 months of control group. 
 
Therefore, therapies should not only be aimed at 
reducing hypercortisolism, but also at the prevention 
and/or control of comorbidities that may occur in the 
short- or long-term if the metabolic disorders associated 
with HAC are not normalised. Paradoxically, even after 
reducing hypercortisolism, the adverse effects of 
comorbidities associated with excess glucocorticoids 
can persist for several months (Barahona et al., 2009, 
2010). A previous study by our group reported that the 
use of insulin detemir at low doses helped control the 
metabolic disorders associated with HAC, preventing 
the development of diabetes mellitus (Miceli et al., 
2012). Similarly, in the present study, we observed that 
metformin was associated with decreased blood 
glucose, triglycerides and total cholesterol 
concentrations in dogs with HAC. In diabetic humans, 
it is known that metformin treatment decreases fasting 
hyperglycaemia, and to a lesser extent, postprandial 
hyperglycaemia, without increasing the risk of 
hypoglycaemia (Natali and Ferrannini, 2006; Aroda et 
al., 2015). In dogs, Chu et al. (2000) demonstrated that 
metformin is effective for decreasing hepatic glucose 
production, not so much by inhibiting gluconeogenesis, 
but rather by reducing glycogenolysis. The mechanism 
of action of metformin remains controversial, and it is 
not currently known exactly which receptor it binds. 
However, several studies have shown that metformin 
acts on AMPK (cAMP-activated protein kinase), an 
enzyme complex that is activated by increasing the 
AMP:ATP ratio (Rena et al., 2013; Foretz et al., 2014; 
Hongying and Ling, 2016). In contrast, some dogs with 
HAC that were not treated with metformin showed 
increased levels of glucose and triglycerides, despite 
having started the treatment for HAC. These increases 
may be due to individual differences of each dog to 
either the severity of the disease, resistance to therapy 
with ketoconazole or cabergoline, or persistence of the 
adverse effects of hypercortisolism (Vegiopoulos and 
Herzig, 2007; Castillo et al., 2008; Barahona et al., 
2010; Miceli et al., 2012, 2017). To date, no studies 
have described the effects of metformin in dogs with 
HAC, but there have been several reports in diabetic 
cats. Nelson et al. (2004) evaluated the use of 
metformin to treat cats with diabetes mellitus, obtaining 
satisfactory results only in animals with a good insulin 
reserve. This is also the case for dogs with HAC that 
also present insulin resistance and hyperinsulinism 
(Montgomery et al., 1996; Miceli et al., 2014), which 
explains why the insulin-sensitising effect of 
metformin would be useful. Treatment of HAC with 
ketoconazole and cabergoline was found to be effective 
for reducing UCCR, and thus, controlling the clinical 
signs of the disease. Once hypercortisolism is 
controlled, the degree of hyperinsulinism, insulin 
resistance (indicated by increased HOMAinsulin sensitivity) 
and pancreatic β-cell functionality (indicated by 
decreased HOMAβ-cell function) is simultaneously 
decreased. In this study, we used ketoconazole rather 
than retinoic acid (isotretinoin 9-cis) (Castillo et al., 
2006) because patients receiving retinoids may present 
dyslipidaemia as an adverse effect (Lilley et al., 2013). 
The most interesting observation of the current study 
was that the administration of metformin, combined 
with ketoconazole treatment for HAC, caused a further 
reduction in the hyperinsulinism and insulin resistance 
of patients, as well as improved pancreatic β-cell 
functionality. By reducing hepatic glucose production 
(Chu et al., 2000; Hongying and Ling, 2016), 
metformin indirectly decreases the insulin requirement 
to maintain glycaemic homeostasis. Furthermore, due 
to its insulin-sensitising effects on adipose tissue and 
skeletal muscle (Natali and Ferrannini, 2006), 
metformin also decreases the peripheral insulin 
resistance in dogs with HAC. The use of metformin in 
dogs with HAC was associated with the same adverse 
effects observed in humans, including diarrhoea, 
inappetence and vomiting (Hostalek et al., 2015). No 
lactic acidosis or haematological disorders were 
http://www.openveterinaryjournal.com 




observed, at least 3 months after therapy. Adverse 
gastrointestinal effects were controlled by gradually 
increasing the metformin dose. When the gradual 
dosage of metformin and the contraindications in 
humans, such as liver and kidney disease (Foretz et al., 
2014; Hostalek et al., 2015), are considered, metformin 
represents a drug that can not only effectively improve 
insulin sensitivity and reduce the glycaemia of humans, 
cats and dogs, but is also safe to use. For future 
research, the long-term effects of metformin and its 
beneficial effects on other systems or diseases, such as 
cardiovascular disease, obesity, inflammation or 
cancer, will be assessed (Mahmood et al., 2013). The 
implementation of metformin as an adjuvant therapy is 
effective for normalising and improving glycaemia, 
triglyceridaemia, cholesterolaemia and insulinaemia in 
dogs with HAC, at least within the first 3 months of 
treatment. In addition, metformin reduced the insulin 
resistance and improved the pancreatic β-cell function 
in dogs with HAC. Dogs represent an excellent model 
for HAC study, and the results obtained have an 
interesting potential for translation to human medicine. 
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